Edition:
India

DiaMedica Therapeutics Inc (DMAC.OQ)

DMAC.OQ on NASDAQ Stock Exchange Capital Market

3.40USD
12 Dec 2019
Change (% chg)

-- (--)
Prev Close
$3.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
10,679
52-wk High
$5.90
52-wk Low
$1.71

Summary

Name Age Since Current Position

Richard Pilnik

57 2014 Independent Chairman of the Board

Rick Pauls

2014 President, Chief Executive Officer, Director

Scott Kellen

51 2018 Chief Financial Officer, Corporate Secretary

Sydney Gilman

2019 Vice President - Regulatory Affairs

Paul Papi

2016 Vice President - Business Development

Harry Alcorn

57 2018 Director

James Parsons

2018 Director

Jerry Xiao

2016 Director

Michael Giuffre

2010 Independent Director

Biographies

Name Description

Richard Pilnik

Mr. Richard D. Pilnik (Rich) serves as an Independent Chairman of the Board of DiaMedica Inc. Mr. Pilnik has been a member of DiaMedica's Board of Directors since 2009. He recently retired as Executive Vice President and President of Quintiles Commercial Solutions, a global pioneer in pharmaceutical services. Mr. Pilnik previously spent 25 years at Eli Lilly, where he held several leadership positions including Group Vice President and Chief Marketing Officer. As President of Eli Lilly Europe, Middle East and Africa and the Commonwealth of the independent States (CIS), a regional organization of former Soviet Republics, he oversaw 50 countries and positioned Eli Lilly as the fastest growing pharmaceutical company in the region. During his tenure at Eli Lilly, Mr. Pilnik also held several marketing and sales management positions in the United States, Europe and Latin America. Mr. Pilnik has served on the board of directors of Elan Corporation, a successful bio-pharmaceutical company focused on neurodegenerative diseases, prior to the company being acquired in 2013. He holds a Bachelor of Arts in Economics from Duke University and an MBA from the Kellogg School of Management at Northwestern University. He currently sits on the board of the Duke University Fuqua School of Business and Elan Pharmaceuticals.

Rick Pauls

Mr. Rick Pauls, MBA., serves as the President, Chief Executive Officer, Director of DiaMedica Inc. Mr. Rick Pauls was appointed President and CEO of DiaMedica in July 2009 and has been Chairman of the board of directors since 2008. Mr. Pauls was previously the Managing Director of CentreStone Ventures Inc., an early stage life sciences venture capital fund. Prior to CentreStone, he was with Centara Corporation, another early stage venture capital fund. Before this, Mr. Pauls specialized in asset-backed securitization and structured finance with General Motors Acceptance Corporation in Minnesota. He received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota. Mr. Pauls also sits on the board of LED Medical Diagnostics Inc.

Scott Kellen

Mr. Scott Kellen is Chief Financial Officer, Corporate Secretary of the Company. Mr. Kellen is a highly qualified senior executive with corporate board experience. He has held positions as Chief Operating Officer and Chief Financial Officer within publicly traded healthcare companies, most recently as CFO for Sun Bio Pharma. In addition to the positions he has played, Mr. Kellen has significant experience with capital formation, public company reporting and corporate governance. Mr. Kellen has held a Certified Public Accountant certificate, and graduated summa cum laude from the University of South Dakota with a Bachelor of Science in Business Administration.

Sydney Gilman

Dr. Sydney Gilman, Ph.D. is appointed as Vice President - Regulatory Affairs of the Company effective November 1, 2019. Dr. Gilman is currently the founder and President of Trident Rx Consulting Services LLC, a regulatory consulting firm, a position he has held since January 2004. Dr. Gilman is a former U.S. Food and Drug Administration (“FDA”) Chemistry reviewer. He spent six years at the FDA in various Center for Drug Evaluation and Research Therapeutic Drug Divisions of the Center for Drug Evaluation and Research with consulting ties to both Biologics and Devices. Dr. Gilman also has an additional 20 years of experience in the pharmaceutical industry in positions ranging from Senior Scientist to Director to Vice President Responsibilities. He earned a Bachelor of Science degree from Loyola College and a Ph.D. in Organic Chemistry from the University of Pittsburgh. Dr. Gilman has been providing regulatory consulting services to DiaMedica since June 2019.

Paul Papi

Mr. Paul Papi serves as Vice President - Business Development of the Company. Mr. Papi has over 37 years of experience in life sciences, including 25 years at Mylan Pharmaceuticals. His expertise includes executive management in the pharmaceutical industry, investment banking and investor relations.

Harry Alcorn

Dr. Harry W. Alcorn is Director of the Company. Prior to joining Diamedica, Dr. Alcorn served as Chief Scientific Officer at DaVita Clinical Research (DaVita), a company that provides clinical research services for pharmaceutical and biotech companies. During this time, he also served on the Board of Directors for The Association of Clinical Pharmacology Units and on the Board of Directors of MedTox Laboratories. In 2000 Dr. Alcorn started the US Renal Network, the first organization to coordinate clinical trial sites for the conduct of kidney studies. Prior to DaVita he held the position of Executive Director and led the clinical trials at GalaGen Inc, a biopharmaceutical company developing therapeutics to target life-threatening and emerging pathogens. Dr. Alcorn obtained his Bachelor of Pharmacy from Creighton University and his Doctor of Pharmacy from University of Nebraska Medical Center. He currently holds clinical faculty appointments with the University of Minnesota, Creighton University, University of Nebraska Medical Center, Virginia Commonwealth and the University of Colorado, Denver.

James Parsons

Mr. James T. Parsons, CPA., CA., is Director of the Company. He was Corporate Secretary of the Company. He joined company as Corporate Secretary of DiaMedica Inc. He resigned from the position of Vice President - Finance of the Company with effect from 15 January 2015. Mr. Parsons joined DiaMedica in October 2010 with an background in the life sciences industry and over 20 years of financial management experience. Prior to joining DiaMedica, Mr. Parsons was the Chief Financial Officer and Corporate Secretary for Amorfix Life Sciences Ltd. where his responsibilities included finance, administration, contract management, and corporate governance. Mr. Parsons has been a CFO in the life sciences industry since 2000 with early-stage to late-clinical stage biotechnology companies across many diagnostic and therapeutic service areas. He is also currently the Chief Financial Officer of Stem Cell Therapeutics Corp since August 2011. Mr. Parsons has a Master of Accounting degree from the University of Waterloo.

Jerry Xiao

Dr. Jerry Xiao serves as Director of the Company. Dr. Xiao has been the Managing Director of Hermed Capital since December 2014 and previously was the head of Business Development and Associate General Manager of the Research and Development Center of Shanghai Fosun Pharmaceutical Group from June 2008 to November 2014 where he was the deputy chief of the IPO team for the Fosun Pharma Listing in Hong Kong.

Michael Giuffre

Dr. Michael Giuffre, M.D., serves as an Independent Director of DiaMedica Inc. As a Clinical Professor of Cardiac Sciences and Pediatrics at the University of Calgary, Dr. Giuffre maintains a portfolio of clinical practice, cardiovascular research, and university teaching. He maintains ongoing involvement in both health care administration, and in the biotechnology business sector. Dr. Giuffre is Past President of the Calgary and Area Physicians Association (CAPA) and a past representative to the board of the Calgary Health Region. Dr Giuffre holds a BSc in cellular and microbial biology, an MD and an MBA. His Canadian Royal College board certified specialties include Pediatrics, Pediatric Cardiology and a subspecialty in Pediatric Electrophysiology. As a biotechnology consultant, Dr. Giuffre has been involved with RedSky Inc. (acquired by Research in Motion), MDMI, and MedMira Inc. He is currently on the boards of IC2E Inc and FoodChek Inc. He serves on the Medical Advisory Board of the SADS Foundation and on the boards of Unicef Canada and the Alberta Medical Association. He is also an MDMP contact for the Canadian Medical Association. Dr. Giuffre has recently received a Certified and Registered Appointment by the American Academy of Cardiology, “Distinguished Fellow of the American Academy of Cardiology,” and in 2005 was awarded “Physician of the Year” by the Calgary Medical Society. His Canadian Royal College board certified specialties include Pediatrics and Pediatric Cardiology with a subspecialty in Pediatric Electrophysiology.

Basic Compensation